Current and experimental drug therapy for the treatment of polycystic ovarian syndrome

References

• Teede HJ , Misso ML , Costello MF , et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018;110(3):364–379.
   PubMed Web of Science ®Google Scholar
• Giampaolino P , Della Corte L , De Rosa N , et al. Ovarian volume and PCOS: a controversial issue. Gynecol Endocrinol. 2018 Mar;34(3):229–232.
   PubMed Web of Science ®Google Scholar
• Azziz R , Carmina E , Chen Z , et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057.
   PubMed Web of Science ®Google Scholar
• Li Y , Chen C , Ma Y , et al. Multisystem reproductive metabolic disorder: significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS). Life Sci. 2019;228:167–175.
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004 Jan;81(1):19–25.
   Web of Science ®Google Scholar
• Malini NA , Roy George K. Evaluation of different ranges of LH:FSH ratios in polycystic ovarian syndrome (PCOS) - clinical based case control study. Gen Comp Endocrinol. 2018 May 1;260: 51–57.
   PubMed Web of Science ®Google Scholar
• González F . Inflammation in polycystic ovary syndrome: underpinning of insulin resistance and ovarian dysfunction. Rev Steroids. 2012 Mar 10;77(4):300–305. PMID: 22178787 PMCID: PMC3309040.
   PubMed Web of Science ®Google Scholar
• Abbott DH , Dumesic DA , Levine JE . Hyperandrogenic origins of polycystic ovary syndrome – implications for pathophysiology and therapy. Expert Rev Endocrinol Metab. 2019 Mar;14(2):131–143.
   PubMed Web of Science ®Google Scholar
• González F , Rote NS , Minium J , et al. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 Jan;91(1):336–340.
   PubMed Web of Science ®Google Scholar
• Zafari Zangeneh F , Naghizadeh MM , Masoumi M . Polycystic ovary syndrome and circulating inflammatory markers. Int J Reprod Biomed (Yazd). 2017 Jun;15(6):375–382. PMCID: PMC5605859
   PubMed Web of Science ®Google Scholar
• Kalea AZ , Schmidt AM , Hudson BI . RAGE: a novel biological and genetic marker for vascular disease. Clin Sci (Lond). 2009 Apr;116(8):621–637.
   PubMed Web of Science ®Google Scholar
• Grodnitskaya EE , Kurtser MA . Homocysteine metabolism in polycystic ovary syndrome. Gynecol Endocrinol. 2012 Mar;28(3):186–189. Epub 2011 Jul 27.
   PubMed Web of Science ®Google Scholar
• Hara S , Takahashi T , Amita M , et al. Pioglitazone counteracts the tumor necrosis factor-a inhibition of follicle-stimulating hormone-induced follicular development and estradiol production in an in vitro mouse preantral follicle culture system. J Ovarian Res. 2013 Sep 30;6(1):69.
   PubMedGoogle Scholar
• Abbott DH , Dumesic DA , Levine.Hyperandrogenic JE . Origins of polycystic ovary syndrome – implications for pathophysiology and therapy. Expert Rev Endocrinol Metab. 2019 March;14(2):131–143.
   PubMed Web of Science ®Google Scholar
• Zhao X , Jiang Y , Xi H , et al. Exploration of the relationship between gut microbiota and polycystic ovary syndrome (PCOS): a review. Geburtshilfe Frauenheilkd. 2020 Feb;80(2):161–171. Epub 2020 Feb 21.
   PubMed Web of Science ®Google Scholar
• Consortium HMPc . Structure, function and diversity of the healthy human microbiome. Nature. 2012;486:207–214.
   PubMed Web of Science ®Google Scholar
• Sun L , Hu W , Liu Q , et al. Metabonomics reveals plasma metabolic changes and inflammatory marker in polycystic ovary syndrome patients. J Proteome Res. 2012;11:2937–2946.
   PubMed Web of Science ®Google Scholar
• Zhang D , Zhang L , Yue F , et al. Serum zonulin is elevated in women with polycystic ovary syndrome and correlates with insulin resistance and severity of anovulation. Eur J Endocrinol. 2015;172:29–36.
   PubMed Web of Science ®Google Scholar
• Torres PJ , Siakowska M , Banaszewska B , et al. Gut microbial diversity in women with polycystic ovary syndrome correlates with hyperandrogenism. J Clin Endocrinol Metab. 2018;103:1502–1511.
   PubMed Web of Science ®Google Scholar
• Lourdes I , Oberfield SE , Witchel S , et al. An international consortium update: pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence. Horm Res Paediatr. 2017 November 13. DOI:10.1159/000479371.
   Web of Science ®Google Scholar
• Dunaif A . Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997 Dec;18(6):774–800.
   PubMed Web of Science ®Google Scholar
• Poretsky L . On the paradox of insulin-induced hyperandrogenism in insulin-resistant states. Endocr Rev. 1991 Feb;12(1):3–13.
   PubMed Web of Science ®Google Scholar
• Moghetti P . Advances in the treatment of polycystic ovary syndrome. Expert Opin Investig Drugs. 2001 Sep;10(9):1631–1640.
   PubMed Web of Science ®Google Scholar
• Wolczynski S , Zgliczynski W . Abnormalities of the menstrual cycle. In: Large interna – endocrinology. 2nd ed. Warsaw: Medical Tribune Poland; 2012. p. 561–567.
   Google Scholar
• Kamboj MK , Bonny AE . Polycystic ovary syndrome in adolescence: diagnostic and therapeutic strategies. Transl Pediatr. 2017 Oct;6(4):248–255.
   PubMed Web of Science ®Google Scholar
• Piltonen TT , Ruokojärvi M , Karro H , et al. Awareness of Polycystic Ovary Syndrome Among Obstetrician-Gynecologists and Endocrinologists in Northern Europe. PLoS One. 2019 Dec 26;14(12):e0226074.
   PubMed Web of Science ®Google Scholar
• Costello M , Garad R , Hart R , et al. A review of first line infertility treatments and supporting evidence in women with polycystic ovary syndrome. Med Sci (Basel). 2019 [cited 2019 Sep 10 ];7(9):95.
   Google Scholar
• Mitwally MF , Casper RF . Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril. 2001 Feb; 75(2):305–309.
   PubMed Web of Science ®Google Scholar
• Mejia RB , Summers KM , Kresowik JD , et al. A randomized controlled trial of combination letrozole and clomiphene citrate or letrozole alone for ovulation induction in women with polycystic ovary syndrome. Fertil Steril. 2019;111(3):571–578.e1.
   PubMed Web of Science ®Google Scholar
• Adashi EY . Clomiphene citrate: mechanism(s) and site(s) of action–a hypothesis revisited. Fertil Steril. 1984 Sep;42(3):331–344.
   PubMed Web of Science ®Google Scholar
• Legro RS , Brzyski RG , Diamond MP , et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014 July 10;371(2):119–129.
   PubMed Web of Science ®Google Scholar
• Costello MF , Eden JA . A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril. 2003 Jan; 79(1):1–13.
   PubMed Web of Science ®Google Scholar
• Palomba S , Falbo A , Zullo F , et al. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev. 2009 Feb;30(1):1–50.
   PubMed Web of Science ®Google Scholar
• Tang T , Glanville J , Hayden CJ , et al. Com- bined lifestyle modification and metformin in obese patients with polycystic ovary syndrome: A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod. 2006;21:80–89.
   PubMed Web of Science ®Google Scholar
• Lunenfeld B , Insler V . Classification of amenorrhoeic states and their treatment by ovulation induction. Clin Endocrinol (Oxf). 1974 Apr;3(2):223–237.
   PubMed Web of Science ®Google Scholar
• White DM , Polson DW , Kiddy D , et al. Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. J Clin Endocrinol Metab. 1996 Nov;81(11):3821–3824.
   PubMed Web of Science ®Google Scholar
• Balen AH , Morley LC , Misso M , et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update. 2016;22(6):687–708.
   PubMed Web of Science ®Google Scholar
• Van Santbrink EJ , Donderwinkel PF , van Dessel TJ , et al. Gonadotrophin induction of ovulation using a step-down dose regimen: single-centre clinical experience in 82 patients. Hum Reprod. 1995 May;10(5):1048–1053.
   PubMed Web of Science ®Google Scholar
• Barthelmess EK , Naz RK . Polycystic ovary syndrome: current status and future perspective. Front Biosci (Elite Ed). 2014 Jan 1;6:104–119. PMCID: PMC4341818.
   PubMedGoogle Scholar
• The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, March 2–3, 2007, Thessaloniki, Greece . Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod. 2008;23(3): 462–477.
   PubMed Web of Science ®Google Scholar
• Farquhar C , Brown J , Marjoribanks J . Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev. 2012;(6). Art. No.: CD001122. DOI:10.1002/14651858.CD001122.pub4
   Web of Science ®Google Scholar
• Giampaolino P , Morra I , Della Corte L , et al. Serum anti-Mullerian hormone levels after ovarian drilling for the second-line treatment of polycystic ovary syndrome: a pilot-randomized study comparing laparoscopy and transvaginal hydrolaparoscopy. Gynecol Endocrinol. 2017 Jan;33(1):26–29.
   PubMed Web of Science ®Google Scholar
• Bozdag G , Yildiz BO . Combined oral contraceptives in polycystic ovary syndrome - indications and cautions. Front Horm Res. 2013;40:115–127. Epub 2012 Oct 18. PMID: 24002409.
   PubMed Web of Science ®Google Scholar
• Goodman NF , Cobin RH , Futterweit W , et al. American association of clinical endocrinologists, American college or endocrinology and androgen excess and PCOS society disease state clinical review: guide to the best practices in the evalution and treatment of polycystic ovary syndrome. Endocr Pract. 2015;21:1291–1300.
   PubMed Web of Science ®Google Scholar
• Teede H , Tassone EC , Piltonen T , et al. Effect of the combined oral contraceptive pill and/or metformin in the management of polycystic ovary syndrome: A systematic review with meta-analyses. Clin Endocrinol (Oxf). 2019;91(4):479–489.
   PubMed Web of Science ®Google Scholar
• Krepula K , Bidzinska-Speichert B , Lenarcik A , et al. Psychiatric disorders related to polycystic ovary syndrome. Endokrynol Pol. 2012;63(6):488–491. PMID: 23339008.
   PubMed Web of Science ®Google Scholar
• Mazza A , Fruci B , Guzzi P , et al. In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. Nutr Metab Cardiovasc Dis. 2014 Feb;24(2):132–139.
   PubMed Web of Science ®Google Scholar
• Thuzar M , Law WP , Dimeski G , et al. Mineralocorticoid antagonism enhances brown adipose tissue function in humans: A randomized placebo-controlled cross-over study. Diabetes Obes Metab. 2019;21(3):509–516.
   PubMed Web of Science ®Google Scholar
• Ibáñez L , de Zegher F . Polycystic ovary syndrome in adolescent girls. Pediatr Obes. 2020 Feb;15(2):e12586.
   PubMed Web of Science ®Google Scholar
• Melnik BC . Apoptosis may explain the pharmacological mode of action and adverse effects of isotretinoin, including teratogenicity. Acta Derm Venereol. 2017 Feb 8;97(2):173–181.
   PubMed Web of Science ®Google Scholar
• Sikar Aktürk A , Abali R , Yüksel MA , et al. The effects of isotretinoin on the ovarian reserve of females with acne. Gynecol Endocrinol. 2014 Jan;30(1):30–33.
   PubMed Web of Science ®Google Scholar
• Cakir GA , Erdogan FG , Gurler A . Isotretinoin treatment in nodulocystic acne with and without polycystic ovary syndrome: efficacy and determinants of relapse. Int J Dermatol. 2013 Mar;52(3):371–376.
   PubMed Web of Science ®Google Scholar
• Cetinözman F , Aksoy DY , Elçin G , et al. Insulin sensitivity, androgens and isotretinoin therapy in women with severe acne. J Dermatol Treat. 2014 Apr;25(2):119–122.
   PubMed Web of Science ®Google Scholar
• Vexiau P , Chaspoux C , Boudou P , et al. Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. Br J Dermatol. 2002 Jun;146(6):992–999.
   PubMed Web of Science ®Google Scholar
• Starace M , Orlando G , Alessandrini A , et al. Female androgenetic alopecia: an update on diagnosis and management. Am J Clin Dermatol. 2020;21(1):69–84.
   PubMed Web of Science ®Google Scholar
• Lucky AW , Piacquadio DJ , Ditre CM , et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50:541–553.
   PubMed Web of Science ®Google Scholar
• Olsen EA , Dunlap FE , Funicella T , et al. A randomized clinical trial of 5% topi- cal minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in males. J Am Acad Dermatol. 2002;47:377–385.
   PubMed Web of Science ®Google Scholar
• Blume-Peytavi U , Shapiro J , Messenger AG , et al. Efficacy and safety of once-daily minoxidil foam 5% versus twice-daily minoxidil solution 2% in female pattern hair loss: a phase III, randomized, investigator-blinded study. J Drugs Dermatol. 2016;25:883–889.
   Google Scholar
• Wolf JE Jr , Shander D , Huber F , et al. Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair. Int J Dermatol. 2007 Jan;46(1):94–98.
   PubMed Web of Science ®Google Scholar
• Badr D , Kurban M , Abbas O . Metformin in dermatology: an over- view. J Eur Acad Dermatol Venereol. 2013 Nov 27;27:1329–1335.
   PubMed Web of Science ®Google Scholar
• Legro RS . Obesity and PCOS: implications for diagnosis and treatment. Semin Reprod Med. 2012 Dec;30(6):496–506.
   PubMed Web of Science ®Google Scholar
• Banting LK , Gibson-Helm M , Polman R , et al. Physical activity and mental health in women with polycystic ovary syndrome. BMC Womens Health. 2014 Mar 27;14(1):51.
   PubMed Web of Science ®Google Scholar
• Harrison CL , Stepto NK , Hutchison SK , et al. The impact of intensified exercise training on insulin resistance and fitness in overweight and obese women with and without polycystic ovary syndrome. Clin Endocrinol (Oxf). 2012 Mar;76(3):351–357.
   PubMed Web of Science ®Google Scholar
• Stepto NK , Patten RK , Tassone EC , et al. Exercise recommendations for women with polycystic ovary syndrome: is the evidence enough? Sports Med. 2019 Aug;49(8):1143–1157.
   PubMed Web of Science ®Google Scholar
• Faghfoori Z , Fazelian S , Shadnoush M , et al. Nutritional management in women with polycystic ovary syndrome: a review study. Rev Diabetes Metab Syndr. 2017 Nov; 11(Suppl 1):S429–S432.
   PubMedGoogle Scholar
• Clinicaltrials.gov . Mediterranean diet versus hypocaloric diet in PCOS. [cited 2020 Jun 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02397174
   Google Scholar
• Facchinetti F , Appetecchia M , Aragona C , et al. Experts’ opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond. Expert Opin Drug Metab Toxicol. 2020 Mar;16(3):255–274.
   PubMed Web of Science ®Google Scholar
• Du Q , Yang S , Wang YJ , et al. Effects of thiazolidinediones on polycystic ovary syndrome: A meta-analysis of ran- domized placebo-controlled trials. Adv Ther. 2012;29(9):763–774.
   PubMed Web of Science ®Google Scholar
• Tang H , Shi W , Fu S , et al. Pioglitazone and bladder cancer risk: a systematic review and meta-analysis. Cancer Med. 2018;7(4):1070–1080.
   PubMed Web of Science ®Google Scholar
• Wallach JD , Wang K , Zhang AD , et al. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses. BMJ. 2020 [cited 2020 Feb 5 ];368:l7078.
   PubMedGoogle Scholar
• Malik SM , Traub M . Defining the role of bariatric surgery in poly- cystic ovarian syndrome patients. World J Diabetes. 2012;3(4):71–79.
   PubMedGoogle Scholar
• Butterworth J , Deguara J , Borg CM . Bariatric surgery, polycystic ovary syndrome, and infertility. J Obes. 2016 [cited 2016 Nov 14 ];2016:1871594.
   PubMed Web of Science ®Google Scholar
• Christ JP , Falcone T . Bariatric Surgery Improves Hyperandrogenism, Menstrual Irregularities, and Metabolic Dysfunction Among Women With Polycystic Ovary Syndrome (PCOS). Obes Surg. 2018 Aug;28(8):2171–2177.
   PubMed Web of Science ®Google Scholar
• Colquitt JL , Pickett K , Loveman E , et al. Surgery for weight loss in adults. Rev Cochrane Database Syst Rev. 2014 Aug 8;(8):CD003641. DOI:10.1002/14651858.CD003641.pub4
   Google Scholar
• Lamos EM , Malek R , Davis SN . GLP-1 receptor agonists in the treatment of polycystic ovary syndrome. Expert Rev Clin Pharmacol. 2017;10(4):401–408.
   PubMed Web of Science ®Google Scholar
• Han Y , Li Y , He B . GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis. Reprod Biomed Online. 2019 Aug;39(2):332–342. Epub 2019 Apr 25.
   PubMed Web of Science ®Google Scholar
• Consoli A , Formoso G , Baldassarre MPA , et al. A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment. Expert Opin Drug Saf. 2018;17(3):293–302.
   PubMed Web of Science ®Google Scholar
• Holman RR , Bethel MA , Mentz RJ , et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med [ Internet]. 2017;377(13):1228–1239. NEJMoa1612917.
   Web of Science ®Google Scholar
• Marso SP , Daniels GH , Brown-Frandsen K , et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med [Internet]. 2016 [cited 2017 Nov 2 ];375:311–322.
   PubMed Web of Science ®Google Scholar
• Thomson RL , Spedding S , Brinkworth GD , et al. Seasonal effects on vitamin D status influence outcomes of life- style intervention in overweight and obese women with polycys- tic ovary syndrome. Fertil Steril. 2013;99(6):1779–1785.
   PubMed Web of Science ®Google Scholar
• Rashid A , Ganie MA , Ahmad Wani I , et al. Differential impact of insulin sensitizers vs. anti-androgen on serum leptin levels in Vitamin D replete PCOS women: a six month open labeled randomized study. Horm Metab Res. 2020 Feb;52(2):89–94.
   PubMed Web of Science ®Google Scholar
• Celik O , Acbay O . Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance. J Endocrinol Invest. 2012;35(10):905–910.
   PubMed Web of Science ®Google Scholar
• Pedro-Botet J , Climent E , Benaiges D . Muscle and statins: from toxicity to the nocebo effect. Expert Opin Drug Saf. 2019;18:573–579.
   PubMed Web of Science ®Google Scholar
• Fulghesu AM , Ciampelli M , Muzj G , et al. N-acetyl-cysteine treatment improves insulin sensitivity in women with polycystic ovary syndrome. Clin Trial Fertil Steril. 2002 Jun;77(6):1128–1135.
   PubMed Web of Science ®Google Scholar
• Thakker D , Raval A , Patel I , et al. N-acetylcysteine for polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled clinical trials. Obstet Gynecol Int. 2015;2015:817849.
   PubMed Web of Science ®Google Scholar
• Cheraghi E , Mehranjani MS , Shariatzadeh MA , et al. N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin. Reprod Fertil Dev. 2016 Apr;28(6):723–731.
   PubMed Web of Science ®Google Scholar
• Unfer V , Carlomagno G , Dante G , et al. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol. 2012 Jul;28(7):509–515.
   PubMed Web of Science ®Google Scholar
• Chukwuma CI , Ibrahim MA , Islam MS . Myo-inositol inhibits intestinal glucose absorption and promotes muscle glucose uptake: a dual approach study. J Physiol Biochem. 2016 Dec;72(4):791–801. PubMed PMID: 27601253.
   PubMed Web of Science ®Google Scholar
• Kim JN , Han SN , Kim HK . Phytic acid and myo-inositol support adipocyte differentiation and improve insulin sensitivity in 3T3-L1 cells. Nutr Res. 2014 Aug;34(8):723–731. PubMed PMID: 25174657.
   PubMed Web of Science ®Google Scholar
• FDA . Opinion: inositol 2017. [cited 2020 Jun 1]. Available from: http://wayback.archive-it.org/7993/20171031060738/https://www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/SCO GS/ucm260436.htm
   Google Scholar
• Monastra G , Unfer V , Harrath AH , et al. Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients. Gynecol Endocrinol. 2017 Jan;33(1):1–9. PubMed PMID: 27898267.
   PubMed Web of Science ®Google Scholar
• Le Donne M , Metro D , Alibrandi A , et al. Effects of three treatment modalities (diet, myoinositol or myoinositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome. Eur Rev Med Pharmacol Sci. 2019 Mar;23(5):2293–2301.
   PubMed Web of Science ®Google Scholar
• Permyakov EA , Berliner LJ . Alpha-Lactalbumin: structure and function. FEBS Lett. 2000 May 19;473(3):269–274. PubMed PMID: 10818224.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M , Takai S . Chronic administration of bovine milk-derived alpha-lactalbumin improves glucose tolerance via enhancement of adiponectin in Goto-Kakizaki rats with type 2 diabetes. Biol Pharm Bull. 2014;37(3):404–408. PubMed PMID: 24583859; eng.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M , Yoshida K , Uchida M . Novel functions of bovine milk-derived alpha-lactalbumin: anti- nociceptive and anti-inflammatory activity caused by inhibiting cyclooxygenase-2 and phospholipase A2. Biol Pharm Bull. 2009 Mar;32(3):366–371. PubMed PMID: 19252279; eng.
   PubMed Web of Science ®Google Scholar
• Murri M , Luque-Ramírez M , Insenser M , et al. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Hum Reprod Update. 2013 May-Jun;19(3):268–288.
   PubMed Web of Science ®Google Scholar
• Selva DM , Hammond GL . Thyroid hormones act indirectly to increase sex hormone-binding globulin production by liver via hepatocyte nuclear factor-4alpha. J Mol Endocrinol. 2009 Jul;43(1):19–27.
   PubMed Web of Science ®Google Scholar
• Liu M , Gao J , Zhang Y , et al. Serum levels of TSP-1, NF-?B and TGF-ß1 in polycystic ovarian syndrome (PCOS) patients in northern China suggest PCOS is associated with chronic inflammation. Clin Endocrinol (Oxf). 2015 Dec;83(6):913–922.
   PubMed Web of Science ®Google Scholar
• Ojeda-Ojeda M , Murri M , Insenser M , et al. Mediators of low-grade chronic inflammation in polycystic ovary syndrome (PCOS). Curr Pharm Des. 2013;19(32):5775–5791.
   PubMed Web of Science ®Google Scholar
• Spritzer PM , Lecke SB , Satler F , et al. Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction. 2015 May;149(5):R219–27.
   PubMed Web of Science ®Google Scholar
• Repaci A , Gambineri A , Pasquali R . The role of low-grade inflammation in the polycystic ovary syndrome. Mol Cell Endocrinol. 2011 Mar 15;335(1):30–41.
   PubMed Web of Science ®Google Scholar
• Xiong YL , Liang XY , Yang X , et al. Low-grade chronic inflammation in the peripheral blood and ovaries of women with polycystic ovarian syndrome. Eur J Obstet Gynecol Reprod Biol. 2011 Nov;159(1):148–150.
   PubMed Web of Science ®Google Scholar
• Tzanavari T , Giannogonas P , Karalis KP . TNF-alpha and obesity. Curr Dir Autoimmun. 2010;11:145–156.
   PubMedGoogle Scholar
• Nehir Aytan A , Bastu E , Demiral I , et al. Relationship between hyperandrogenism, obesity, inflammation and polycystic ovary syndrome. Gynecol Endocrinol. 2016 Sep;32(9):709–713.
   PubMed Web of Science ®Google Scholar
• Norman RJ , Brannstrom M . Cytokines in the ovary: pathophysiology and potential for pharmacological intervention. Pharmacol Ther. 1996;69(3):219–236. PubMed: 8783372.
   PubMed Web of Science ®Google Scholar
• Brannstrom M , Norman RJ . Involvement of leukocytes and cytokines in the ovulatory process and corpus luteum function. Hum Reprod. 1993;8:1762–1775. PubMed: 8300842.
   PubMed Web of Science ®Google Scholar
• Terranova PF , Rice VM . Review: cytokine involvement in ovarian processes. Am J Reprod Immunol. 1997 Jan;37(1):50–63. PubMed: 9138453.
   PubMed Web of Science ®Google Scholar
• Figueroa F , Davicino R , Micalizzi B , et al. Macrophage secretions modulate the steroidogenesis of polycystic ovary in rats: effect of testosterone on macrophage pro- inflammatory cytokines. Life Sci. 2012 May 22;90(19–20):733–739. Epub 2012 Mar 28. [PubMed: 22480516].
   PubMed Web of Science ®Google Scholar
• Duleba AJ , Dokras A . Is PCOS an inflammatory process? Fertil Steril. 2012 Jan;97(1):7–12.
   PubMed Web of Science ®Google Scholar
• Fulghesu AM , Sanna F , Uda S , et al. IL-6 serum levels and production is related to an altered immune response in polycystic ovary syndrome girls with insulin resistance. Mediators Inflamm. 2011;2011:389317.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E , Paterakis T , Kandarakis HA . Indices of low-grade inflammation in polycystic ovary syndrome. Ann N Y Acad Sci. 2006 Dec;1092:175–186.
   PubMed Web of Science ®Google Scholar
• Bhatnager R , Jalthuria J , Sehrawat R , et al. Evaluating the association of TNF a promoter haplotype with its serum levels and the risk of PCOS: A case control study. Cytokine. 2019 Feb;114:86–91. Epub 2018 Nov 13.
   PubMed Web of Science ®Google Scholar
• McAllister JM , Modi B , Miller BA , et al. Overexpression of a DENND1A isoform produces a polycystic ovary syndrome theca phenotype. Proc Natl Acad Sci U S A. 2014 Apr 15;111(15):E1519–27.
   PubMed Web of Science ®Google Scholar
• Lang Q , Yidong X , Xueguang Z , et al. ETA-mediated anti-TNF-a therapy ameliorates the phenotype of PCOS model induced by letrozole. PLoS ONE. 2019;14(6):e0217495.
   PubMed Web of Science ®Google Scholar
• Kalhori Z , Mehranjani MS , Azadbakht M , et al. L-Carnitine improves endocrine function and folliculogenesis by reducing inflammation, oxidative stress and apoptosis in mice following induction of polycystic ovary syndrome. Reprod Fertil Dev. 2019 Jan;31(2):282–293.
   PubMed Web of Science ®Google Scholar
• Lee BJ , Lin JS , Lin YC , et al. Anti-inflammatory effects of L-carnitine supplementation (1000 mg/d) in coronary artery disease patients. Nutrition. 2015 Mar;31(3):475–479.
   PubMed Web of Science ®Google Scholar
• Fenkci SM , Fenkci V , Oztekin O , et al. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome. Hum Reprod. 2008 Jul;23(7):1602–1606.
   PubMed Web of Science ®Google Scholar
• Warren-Ulanch J , Arslanian S . Treatment of PCOS in adolescence. Best Pract Res Clin Endocrinol Metab. 2006 Jun;20(2):311–330.
   PubMed Web of Science ®Google Scholar
• Patel SS , Truong U , King M , et al. Obese adolescents with polycystic ovarian syndrome have elevated cardiovascular disease risk markers. Vasc Med. 2017;22(2):85–95.
   PubMed Web of Science ®Google Scholar
• Brennan KM , Kroener LL , Chazenbalk GD , et al. Polycystic ovary syndrome: impact of lipotoxicity on metabolic and reproductive health. Obstet Gynecol Surv. 2019 Apr;74(4):223–231.
   PubMed Web of Science ®Google Scholar
• Faubert J , Battista MC , Baillargeon JP . Physiology and endocrinology symposium: insulin action and lipotoxicity in the development of polycystic ovary syndrome: a review. J Anim Sci. 2016 May;94(5):1803–1811.
   PubMed Web of Science ®Google Scholar
• Løvvik TS , Carlsen SM , Ø S , et al. Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019 Apr;7(4):256–266.
   PubMed Web of Science ®Google Scholar
• Hanem LGE , Stridsklev S , Júlíusson PB , et al. Metformin use in PCOS pregnancies increases the risk of offspring overweight at 4 years of age: follow-up of two RCTs. J Clin Endocrinol Metab. 2018 Apr 1;103(4):1612–1621.
   PubMed Web of Science ®Google Scholar
• Doroszewska K , Milewicz T , Mrozinska S , et al. Blood pressure in postmenopausal women with a history of polycystic ovary syndrome. Prz Menopauzalny. 2019 Jun;18(2):94–98.
   PubMedGoogle Scholar
• Vinaixa M , Rodriguez MA , Samino S , et al. Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy. PLoS One. 2011;6(12):e29052.
   PubMed Web of Science ®Google Scholar